q3 adjusted loss per share $0.61 excluding items.
q1 loss per share $1.76.
qtrly medical end-use sales were down 3% sequentially as customers continue to manage inventory levels as concerns around hospital capacity and potential resurgence weighed on supply chain.
q2 sales $348.8 million versus refinitiv ibes estimate of $352.4 million.
for the balance of year, company currently expects its tax rate to be in range of 28% to 32% for full year 2021.
q1 adjusted operating loss per share $32.3.
qtrly sales excluding surcharge decreased 3% sequentially.
qtrly sales excluding surcharge decreased 34% on 32% lower volume.
qtrly operating loss was $89 million.
qtrly sg&a expenses of $42.2 million, down $13 million from same period a year ago and flat sequentially.
qtrly net sales $300.4 million versus refinitiv ibes estimate of $251.6 million.
qtrly u.s. vehicle inventory remains below 50 days of supply, down about 16% year-over-year.
qtrly net sales $54.1 million versus refinitiv ibes estimate of $55.4 million.
q2 sales decreased 36% on 33% lower volume compared to q2 of 2020.
compname reports q3 earnings per share of $0.25.
q2 adjusted earnings per share $0.22.
